Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
CardioVascular and Interventional Radiology
Published in: CardioVascular and Interventional Radiology 9/2019

01-09-2019 | Interventional Radiology | Clinical Investigation

Current Trends in the Treatment of Hepatocellular Carcinoma with Transarterial Embolization: Variability in Technical Aspects

Authors: Paul Craig, Shamar Young, Jafar Golzarian

Published in: CardioVascular and Interventional Radiology | Issue 9/2019

Login to get access

Abstract

Purpose

While transarterial chemoembolization (TACE) is a mainstay of treatment for unresectable hepatocellular carcinomas (HCCs), technical aspects have varied considerably in the literature. These variations lead to heterogeneity and make meaningful comparisons between articles difficult. The goal of this survey was to report international embolization practices for the treatment of HCC in an effort to understand current treatment strategies as a first step toward technique standardization.

Materials and Methods

An anonymous 18 question online survey, evaluating technical aspects of TACE, was distributed via e-mail to practicing members of the five largest interventional radiology societies in Chinese and English. A total of 1160 responses were obtained from 62 countries.

Results

Between regions, there were significant statistical differences in nearly all responses, including the amount of ethiodol oil used for cTACE (p = < 0.001). Practitioners most commonly used greater than 7.5 ml of ethiodol oil (240/506, 47.4%) and most did not utilize a specific mixing method (249/505, 49.3%). Particles utilized varied by geographical region (p = < 0.001), spherical embolic particles were slightly favored (363/757, 47.9%), followed closely by gelatin-based or sponge particles (279/680, 36.8%). Gelfoam was used almost exclusively in Japan and Korea (79/82 responses). LC/DC beads were the most commonly used drug-eluting bead (DEB) (450/742, 60.6%), with the most common size of DEB being 100–300 μm (354/690, 51.3%, p = 0.07).

Conclusion

Technical aspects of transarterial embolization for HCC vary significantly by geographical location.
Appendix
Available only for authorised users
Literature
1.
Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends—an update. Cancer Epidemiol Prev Biomark. 2016;25(1):16–27.CrossRef
2.
Lai CL, Lok ASF, Wu PC, Chan GCB, Lin HJ. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer. 1988;62(3):479–83.CrossRefPubMed
3.
Varela M, Real MI, Burrel M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol. 2007;46(3):474–81.CrossRefPubMed
4.
Hong K, Khwaja A, Liapi E, Torbenson MS, Georgiades CS, Geschwind J-FH. New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res. 2006;12(8):2563–7.CrossRefPubMed
5.
Kan Z, Sato M, Ivancev K, et al. Distribution and effect of iodized poppyseed oil in the liver after hepatic artery embolization: experimental study in several animal species. Radiology. 1993;186(3):861–6.CrossRefPubMed
6.
de Baere T, Arai Y, Lencioni R, et al. Treatment of liver tumors with lipiodol TACE: technical recommendations from experts opinion. Cardiovasc Intervent Radiol. 2016;39(3):334–43.CrossRefPubMed
7.
Gaba RC. Chemoembolization practice patterns and technical methods among interventional radiologists: results of an online survey. Am J Roentgenol. 2012;198(3):692–9.CrossRef
8.
Bargellini I, Florio F, Golfieri R, Grosso M, Lauretti DL, Cioni R. Trends in utilization of transarterial treatments for hepatocellular carcinoma: results of a survey by the Italian Society of Interventional Radiology. Cardiovasc Intervent Radiol. 2014;37(2):438–44.CrossRefPubMed
9.
Gaba RC, Baerlocher MO, Nikolic B, Venkatesan AM, Lewandowski RJ. Clinical and imaging follow-up practices after transarterial therapy for primary and secondary hepatic malignancies: results of an online survey. Acad Radiol. 2015;22(12):1510–5.CrossRefPubMed
10.
11.
Llovet JM, Real MI, Montaña X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359(9319):1734–9.CrossRefPubMed
12.
Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35(5):1164–71.CrossRefPubMed
13.
Raoul J, Heresbach D, Bretagne J, et al. Chemoembolization of hepatocellular carcinomas a study of the biodistribution and pharmacokinetics of doxorubicin. Cancer. 1992;70(3):585–90.CrossRefPubMed
14.
Nakamura H, Hashimoto T, Oi H, Sawada S. Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology. 1989;170(3):783–6.CrossRefPubMed
15.
Kan Z, Wright K, Wallace S. Ethiodized oil emulsions in hepatic microcirculation: in vivo microscopy in animal models. Acad Radiol. 1997;4(4):275–82.CrossRefPubMed
16.
Lee K-H, Liapi E, Ventura VP, et al. Evaluation of different calibrated spherical polyvinyl alcohol microspheres in transcatheter arterial chemoembolization: VX2 tumor model in rabbit liver. J Vasc Interv Radiol. 2008;19(7):1065–9.CrossRefPubMedPubMedCentral
17.
Koçyiğit A, Dicle O, Göktay Y, Astarcıoğlu İ. The effect of using different embolic agents on survival in transarterial chemoembolization of hepatocellular carcinoma: gelfoam versus polyvinyl alcohol. Diagn Interv Radiol. 2014;20(4):323.CrossRefPubMedPubMedCentral
18.
Bonomo G, Pedicini V, Monfardini L, et al. Bland embolization in patients with unresectable hepatocellular carcinoma using precise, tightly size-calibrated, anti-inflammatory microparticles: first clinical experience and one-year follow-up. Cardiovasc Intervent Radiol. 2010;33(3):552–9.CrossRefPubMed
19.
Stampfl S, Bellemann N, Stampfl U, et al. Inflammation and recanalization of four different spherical embolization agents in the porcine kidney model. J Vasc Interv Radiol. 2008;19(4):577–86.CrossRefPubMed
20.
Malagari K, Pomoni M, Spyridopoulos TN, et al. Safety profile of sequential transcatheter chemoembolization with DC Bead™: results of 237 hepatocellular carcinoma (HCC) patients. Cardiovasc Intervent Radiol. 2011;34(4):774–85.CrossRefPubMed
21.
de Baere T, Plotkin S, Yu R, Sutter A, Wu Y, Cruise GM. An in vitro evaluation of four types of drug-eluting microspheres loaded with doxorubicin. J Vasc Interv Radiol. 2016;27(9):1425–31.CrossRefPubMed
22.
Martin R, Irurzun J, Munchart J, et al. Optimal technique and response of doxorubicin beads in hepatocellular cancer: bead size and dose. Korean J Hepatol. 2011;17(1):51.CrossRefPubMedPubMedCentral
23.
Lee K-H, Liapi E, Vossen JA, et al. Distribution of iron oxide—containing Embosphere particles after transcatheter arterial embolization in an animal model of liver cancer: evaluation with MR imaging and implication for therapy. J Vasc Interv Radiol. 2008;19(10):1490–6.CrossRefPubMedPubMedCentral
24.
Lencioni R, De Baere T, Burrel M, et al. Transcatheter treatment of hepatocellular carcinoma with Doxorubicin-loaded DC Bead (DEBDOX): technical recommendations. Cardiovasc Intervent Radiol. 2012;35(5):980–5.CrossRefPubMed
25.
Lewis AL, Taylor RR, Hall B, Gonzalez MV, Willis SL, Stratford PW. Pharmacokinetic and safety study of doxorubicin-eluting beads in a porcine model of hepatic arterial embolization. J Vasc Interv Radiol. 2006;17(8):1335–43.CrossRefPubMed
Metadata
Title
Current Trends in the Treatment of Hepatocellular Carcinoma with Transarterial Embolization: Variability in Technical Aspects
Authors
Paul Craig
Shamar Young
Jafar Golzarian
Publication date
01-09-2019
Publisher
Springer US
Published in
CardioVascular and Interventional Radiology / Issue 9/2019
Print ISSN: 0174-1551
Electronic ISSN: 1432-086X
DOI
https://doi.org/10.1007/s00270-019-02232-7

Other articles of this Issue 9/2019

CardioVascular and Interventional Radiology 9/2019 Go to the issue

Review

New European Regulation for Medical Devices: What Is Changing?

EDITORIAL

Introduction to the CVIR Special Issue with a Focus on Oncological Interventions

Editorial

CVIR Editors’ Medal 2019

Letter to the Editor

Confirmation of no Common Femoral Artery Stenosis Following Percutaneous EVAR

Clinical Investigation

Restenosis Rates After Drug-Eluting Stent Treatment for Stenotic Small-Diameter Renal Arteries

Letter to the Editor

Re: de Assis et al. “Effects of Prostatic Artery Embolization on the Dynamic Component of Benign Prostate Hyperplasia as Assessed by Ultrasound Elastography: A Pilot Series”